Details
Stereochemistry | ACHIRAL |
Molecular Formula | C28H30N6OS |
Molecular Weight | 498.642 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CC2=CC=C(C=C2)C(=O)NC3=CC=C(C)C(NC4=NC(=CS4)C5=CN=CC=C5)=C3)CC1
InChI
InChIKey=WJEOLQLKVOPQFV-UHFFFAOYSA-N
InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)
Molecular Formula | C28H30N6OS |
Molecular Weight | 498.642 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases. AB Science is developing masitinib in multiple sclerosis and alzheimer's disease. Masitinib targets kinases, including c-Kit, PDGFR, and Lyn. It is used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1936 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19789626 |
200.0 nM [IC50] | ||
Target ID: CHEMBL2007 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19789626 |
540.0 nM [IC50] | ||
Target ID: CHEMBL1913 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19789626 |
800.0 nM [IC50] | ||
Target ID: CHEMBL3905 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19789626 |
510.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Masivet Approved UseTreatment of non-resectable dog mast cell tumours (Grade 2 or 3) with confirmed mutated c-kit
tyrosine kinase receptor. Launch Date1.22549764E12 |
PubMed
Title | Date | PubMed |
---|---|---|
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications]. | 2008 Jan |
|
More about masitinib. | 2009 |
|
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. | 2009 Sep |
|
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. | 2009 Sep 30 |
|
[New drugs for small animals in 2009]. | 2010 |
|
c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis. | 2010 |
|
Churg and Strauss vasculitis in the course of masitinib treatment: a first report. | 2010 Aug |
|
Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. | 2010 Mar 4 |
|
Drug-induced minimal change nephropathy in a dog. | 2010 Mar-Apr |
|
Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). | 2010 May |
|
The complexity of the complicity of mast cells in cancer. | 2010 May |
|
Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. | 2010 Nov |
|
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. | 2010 Nov 24 |
|
Clinical trial on the efficacy of masitinib in canine IBD. | 2010 Nov 6 |
|
Comprehensive analysis of kinase inhibitor selectivity. | 2011 Oct 30 |
|
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. | 2011 Oct 30 |
|
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. | 2013 Apr 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01470131
6 mg/kg/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19789626
In Ba/F3 cells expressing human wild-type Kit, Masitinib inhibits SCF (stem cell factor)-induced cell proliferation with an IC50 of 150 nM, while the IC50 for inhibition of IL-3-stimulated proliferation is at approximately >10 µM. In Ba/F3 cells expressing PDGFRα, Masitinib inhibits PDGF-BB-stimulated proliferation and PDGFRα tyrosine phosphorylation with IC50 of 300 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:06:17 UTC 2023
by
admin
on
Fri Dec 15 16:06:17 UTC 2023
|
Record UNII |
M59NC4E26P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1967
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/04/251
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
||
|
WHO-VATC |
QL01XE22
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
||
|
FDA ORPHAN DRUG |
285309
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
||
|
FDA ORPHAN DRUG |
210505
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
MASIVIERA (REFUSED: PANCREATIC NEOPLASMS)
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/05/286
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
||
|
FDA ORPHAN DRUG |
201005
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
MASICAN (REFUSED: GASTROINTESTINAL STROMAL TUMORS)
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
||
|
FDA ORPHAN DRUG |
201505
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/04/251
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/04/242
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
EU/3/04/251(POSITIVE)
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
PRIMARY | TREATMENT OF MALIGNANT GASTROINTESTINAL STROMAL TUMOURS 20/12/2004 POSITIVE | ||
|
63450
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
PRIMARY | |||
|
DTXSID001000207
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
PRIMARY | |||
|
100000124415
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
PRIMARY | |||
|
790299-79-5
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
PRIMARY | |||
|
C79910
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
PRIMARY | |||
|
Masitinib
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
PRIMARY | |||
|
CHEMBL1908391
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
PRIMARY | |||
|
10074640
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
PRIMARY | |||
|
DB11526
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
PRIMARY | |||
|
C526575
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
PRIMARY | |||
|
M59NC4E26P
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
PRIMARY | |||
|
8779
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
PRIMARY | |||
|
m7092
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
PRIMARY | Merck Index | ||
|
SUB32266
Created by
admin on Fri Dec 15 16:06:17 UTC 2023 , Edited by admin on Fri Dec 15 16:06:17 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
INHIBITOR
|
||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |